Analysts at Northland Securities assumed coverage on shares of Aytu Bioscience (NASDAQ:AYTU) in a research report issued on Friday, Stock Target Advisor reports. The firm set a “buy” rating and a $5.00 price target on the stock.
Other equities research analysts have also issued research reports about the stock. ValuEngine lowered shares of Aytu Bioscience from a “buy” rating to a “hold” rating in a research note on Monday, November 11th. Zacks Investment Research lowered shares of Aytu Bioscience from a “buy” rating to a “hold” rating in a research note on Thursday, October 3rd. Finally, LADENBURG THALM/SH SH lifted their price objective on shares of Aytu Bioscience from $4.00 to $4.75 in a research note on Wednesday, September 18th.
Shares of NASDAQ AYTU traded down $0.15 during trading on Friday, hitting $0.83. The company had a trading volume of 333,700 shares, compared to its average volume of 92,184. Aytu Bioscience has a 52 week low of $0.68 and a 52 week high of $2.61. The business’s 50-day moving average is $1.11 and its 200 day moving average is $1.54. The company has a market cap of $20.32 million, a P/E ratio of -0.24 and a beta of 4.63.
Aytu Bioscience (NASDAQ:AYTU) last released its quarterly earnings data on Thursday, November 14th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). Aytu Bioscience had a negative net margin of 390.43% and a negative return on equity of 199.54%. The business had revenue of $1.44 million during the quarter, compared to analyst estimates of $1.45 million. As a group, equities research analysts expect that Aytu Bioscience will post -0.64 earnings per share for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Aytu Bioscience in the 2nd quarter valued at $36,000. Searle & CO. lifted its stake in shares of Aytu Bioscience by 24.1% in the 3rd quarter. Searle & CO. now owns 249,848 shares of the company’s stock valued at $302,000 after purchasing an additional 48,601 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Aytu Bioscience in the 2nd quarter valued at $75,000. 15.66% of the stock is owned by institutional investors and hedge funds.
Aytu Bioscience Company Profile
Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.
Recommended Story: 52-week highs
Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.